breast

NYSE Content Advisory: Pre-Market Update + Automakers await 5-year tariff relief extension

NEW YORK, Oct. 17, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from…

3 days ago

NYSE Content Advisory: Pre-Market Update + HPE Unveils Strategic Business Priorities

NEW YORK, Oct. 16, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from…

3 days ago

NCCN Guidelines Navigator for Breast Cancer Genetic Testing and Treatment Debuts During Breast Cancer Awareness Month

The National Comprehensive Cancer Network expands interactive library of evidence-based, expert consensus-driven cancer care guidance to now cover treatment for…

2 weeks ago

Pierre Fabre Laboratories Announces Global Partnership with Know Your Lemons Foundation for Breast Cancer Awareness Month

Innovative Campaign Focuses on Early Detection and Empowering Education Throughout October CASTRES, France, Sept. 29, 2025 /PRNewswire/ -- Pierre Fabre Laboratories…

3 weeks ago

SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer

BOSTON, Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion…

4 weeks ago

New mobile units to drive early breast cancer detection in Alberta

EDMONTON, Alberta, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Breast cancer screening is now being performed in two brand-new mobile units…

4 weeks ago

SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes

BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a…

2 months ago

New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options

The TUXEDO-3 trial is the first study to evaluate the intracranial and extracranial efficacy and safety of a novel anti-cancer…

5 months ago

New data show Roches Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced…

5 months ago